Abstract 341P
Background
Preclinical evidence using mouse model suggests that thermal/cold stress increases tumor growth by modulating the tumor microenvironment; however, the clinical relevance of temperature on BC outcomes is unknown. Studies show that residing in cold regions is associated with higher incidence of BC. We aim to study the impact of environmental temperature on the pathological complete response (pCR) and survival of early-stage BC patients (pts).
Methods
A multi-institutional study was conducted within the Oncology Research Information Exchange Network. We analyzed the clinical and genomic data for early-stage BC pts from 12 centers in the United States from different environment zones (5 warm (W) and 7 cold (C)) (based on average annual regional temperature obtained from National Centers for Environmental Information). Cox regression was used to measure the association of climate and overall/relapse-free survival (OS/RFS) after adjusting for confounders.
Results
Out of the 1,304 early-stage BC pts, 271 pts received neoadjuvant chemotherapy (NAC) (186 W, 85 C). Higher clinical T- and N-stages were observed in pts from W compared to C regions (p<0.001). Pts residing in C regions had more comorbidities (57.6% vs 48%, p<0.001). Pts in W regions had higher pCR, though not statistically significant (8% vs 2.5%, p= 0.1). The OS (univariate (UV) HR= 0.48, 95% CI 0.27-0.64, p <0.001; multivariate (MV) aHR= 0.56, 95% CI 0.32 - 0.96, p= 0.03) and RFS (UV HR= 0.51, 95% CI 0.38 - 0.68, p<0.001; MV aHR= 0.52, 95% CI 0.36 - 0.75, p= 0.0005) were higher in pts from W compared to C regions (Table). The OS (aHR= 0.35, p= 0.02) and RFS (aHR= 0.49, p= 0.02) of pts who received NACT were also higher in W regions. Table: 341P
| Regions (n) | 5-yr OS (95% CI) | Median OS (months) (95% CI) | 5-yr RFS (95% CI) | Median RFS (95% CI) | p-value |
| Cold (782) | 83 (76-86) % | 157.7 (116.6-NR) | 69 (62-76) % | 108.4 (88.9-147.8) | <0.001 |
| Warm (522) | 95 (92-97) % | 214.7 (205.3-NR) | 83 (79-87) % | 250.4 (129.9-250.4) |
Conclusions
Early-stage BC pts living in cold have worse OS and RFS compared to warm regions. Larger studies are warranted to validate these interesting findings and further research focusing on therapeutic strategies to abrogate this outcome disparity by temperature is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A.M. Roy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
371P - Adherence to standardized and structured electronic symptom reporting (ePRO) via mobile app in HER2-positive breast cancer treated with HER2 biosimilar trastuzumab
Presenter: Andreas Trojan
Session: Poster session 03
372P - Prevalence of BRCA1 and BRCA2 mutation among Indian breast cancer patients: A multicentre cross-sectional study
Presenter: Shona Nag
Session: Poster session 03
374P - Evaluation of symptom severity, tolerability, and physical function in the I-SPY2 trial
Presenter: Amrita Basu
Session: Poster session 03
375TiP - A phase I, 2-part, multicenter, first-in-human dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors
Presenter: Ludimila Cavalcante
Session: Poster session 03
388P - Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC)
Presenter: Junji Tsurutani
Session: Poster session 03
391P - Detrimental effect on overall survival of CDK4/6 inhibitor dose reduction if immortal time bias is considered
Presenter: Andreas Bjerrum
Session: Poster session 03
392P - The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer on first-line endocrine therapy with or without a CDK 4/6 inhibitor
Presenter: Senna Lammers
Session: Poster session 03